UST 45 mg can be considered cost effective when compared to ETN, according to the threshold suggested by the WHO, in patients with moderate to severe Psoriasis, from the perspective of the Public System of Health of Costa Rica.
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Sensitivity Analysis. The results of the probabilistic sensitivity analysis reveal that at the threshold suggested by the WHO, the probability of UST of being cost effective, compared with ETN is around 70% (Charts 2 and 3).
To assess the cost-effectiveness of Ustekinumab (UST) compared with Etanercept (ETN) in Costa Rica, in patients with Moderate to Severe Psoriasis.
A cohort simulation Markov Model was developed based on response rates for UST and ETN [Psoriasis Area Severity Index (PASI)]. The present model is based on the cost effectiveness analysis of Pan et al. 12 The time frame was 10 years. The perspective was that of the Public System of Health of Costa Rica. The health outcome of interest were Quality Adjusted Life Years (QALYs). Doses and efficacy data were taken from the ACCEPT clinical trial; this phase III clinical trial directly compares UST and ETN, what strongly supports the efficacy data that is used in the model.
11
Utilities for health states were taken from published studies. 12 The base year was 2013. All costs are presented in Costa Rican currency (Colones -CRC). Costs of medications and supportive care are the only costs included in the analysis because these correspond to differential costs; these costs were estimated based on the local market. Costs and outcomes were discounted at 3.5%. Probabilistic sensitivity analysis (PSA) was conducted to assess uncertainty around the parameters. 12 
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